Esperion clears key U.S. antitrust hurdle for merger
I'm LongbridgeAI, I can summarize articles.Esperion Therapeutics announced that the Hart-Scott-Rodino antitrust waiting period for its planned merger with Essence Parent Inc. expired on June 15, 2026, clearing a key regulatory hurdle. The transaction requires stockholder approval at a virtual special meeting on July 8, 2026, and satisfaction of other closing conditions before completion.
The latest announcement is out from Esperion ( (ESPR) ).
Esperion Therapeutics, Inc. announced that the Hart-Scott-Rodino antitrust waiting period for its planned merger with Essence Parent Inc., an affiliate of ArchiMed SAS, expired on June 15, 2026, clearing a key regulatory hurdle. The transaction, under which Esperion will become a wholly owned subsidiary of Essence Parent, still requires approval by Esperion stockholders at a virtual special meeting scheduled for July 8, 2026, and the satisfaction of other customary closing conditions before it can be completed.
The most recent analyst rating on (ESPR) stock is a Hold
with a $3.16 price target.
To see the full list of analyst forecasts on Esperion stock,
see the ESPR Stock Forecast page.
Spark’s Take on ESPR Stock
According to Spark, TipRanks’ AI Analyst, ESPR is a Neutral.
The score is held back primarily by financial fragility (negative equity and ongoing negative free cash flow) despite a strong revenue and operating-profitability turnaround. Technicals are constructive but somewhat overextended (RSI ~72). Valuation is constrained by negative earnings, while recent corporate events—especially the acquisition agreement and regulatory progress—provide meaningful upside support.
To see Spark’s full report on ESPR stock,
click here.
More about Esperion
Esperion Therapeutics, Inc. is a Delaware-based biopharmaceutical company focused on developing and commercializing therapies, particularly in the cardiovascular and metabolic disease space. The company’s primary activities center on innovative treatments aimed at addressing unmet medical needs in lipid management and related conditions.
Average Trading Volume: 12,230,733
Technical Sentiment Signal: Buy
Current Market Cap: $811.7M
For an in-depth examination of ESPR stock, go to TipRanks’ Overview page.